Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Sells $226,697.56 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 14,692 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $15.43, for a total value of $226,697.56. Following the completion of the sale, the chief financial officer now owns 1,402,862 shares of the company’s stock, valued at approximately $21,646,160.66. This represents a 1.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Thomas Freeman also recently made the following trade(s):

• On Thursday, March 6th, Robert Thomas Freeman sold 218,295 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.53, for a total transaction of $3,390,121.35.
• On Tuesday, March 4th, Robert Thomas Freeman sold 250,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.58, for a total transaction of $3,895,000.00.

Alignment Healthcare Stock Performance

ALHC stock traded down $0.21 during midday trading on Thursday, reaching $15.50. 1,216,078 shares of the company’s stock traded hands, compared to its average volume of 2,088,706. The company has a 50-day moving average price of $14.22 and a two-hundred day moving average price of $12.34. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60. Alignment Healthcare, Inc. has a 52 week low of $4.46 and a 52 week high of $16.25. The firm has a market capitalization of $2.97 billion, a PE ratio of -20.13 and a beta of 1.49.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Alignment Healthcare by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,963 shares of the company’s stock valued at $641,000 after acquiring an additional 2,154 shares during the last quarter. Rhumbline Advisers boosted its position in Alignment Healthcare by 2.2% during the fourth quarter. Rhumbline Advisers now owns 135,704 shares of the company’s stock valued at $1,527,000 after buying an additional 2,937 shares during the period. MetLife Investment Management LLC boosted its position in Alignment Healthcare by 5.6% during the fourth quarter. MetLife Investment Management LLC now owns 61,344 shares of the company’s stock valued at $690,000 after buying an additional 3,256 shares during the period. Alliancebernstein L.P. boosted its position in Alignment Healthcare by 2.8% during the fourth quarter. Alliancebernstein L.P. now owns 119,440 shares of the company’s stock valued at $1,344,000 after buying an additional 3,300 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its position in Alignment Healthcare by 15.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 34,497 shares of the company’s stock valued at $388,000 after buying an additional 4,497 shares during the period. Institutional investors own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ALHC. Barclays lifted their target price on shares of Alignment Healthcare from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $17.00 price target on shares of Alignment Healthcare in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Alignment Healthcare in a report on Friday, February 28th. Stifel Nicolaus lifted their price target on shares of Alignment Healthcare from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Bank of America lifted their price target on shares of Alignment Healthcare from $15.50 to $18.50 and gave the stock a “buy” rating in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $14.83.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.